The alpha-beta blocker, marketed by Glaxo as Trandate and by Schering as Normodyne, has been added to the Medi-Cal formulary, making the drug reimbursable under California's Medicaid plan. Labetalol has been shown to be particularly effective in black hypertensives, a group which has not responded well to traditional beta blockers, according to a Glaxo press release.
You may also be interested in...
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.